Search

Semaglutide

[L41335] On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.

Thonzylamine

Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

Hydrochlorothiazide

[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.[L8444]

Besifloxacin

FDA approved on May 28, 2009.

Alirocumab

From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. … Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of

Racepinephrine

Racepinephrine is a racemic mixture consisting of d-DB00668 and l-DB00668 enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermitt...

Potassium bicarbonate

[T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.[L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient.

Ferric carboxymaltose

It was FDA approved on July 25, 2013.

Atezolizumab

[L7489] Atezolizumab was granted FDA approval on 18 October 2016.

Chromous sulfate